Nicolas Hervé Delaleu, PhD

Director, Head of Computational Biology & AI | Accelerating drug development via data-driven decision making | Immunology & Precision Medicine | Creator at the fault lines of Science and Art

E-mail:	nicolas.delaleu@2cSysBioMed.com
LinkedIn:	https://linkedin.com/in/delaleu
Phone:	+41 77 477 82 75
Location:	Switzerland, Lausanne
Date of birth:	18. 11. 1977
Citizenships:	Swiss / French

PROFILE

To enable and accelerate drug discovery and development in order to deliver precision medicine, I intersect data science and machine learning with biotechnology, molecular medicine, and immunotherapy.

With 25+ years of experience gained in academia, leading a contract research organization (CRO) and in the pharmaceutical industry, I deliver actionable and communicable results adequate for data-driven decision making at the intersection of science, medical experts and business strategy.

Therapeutic areas I was involved with include oncology, rheumatology, nephrology and dermatology and span from translational preclinical drug discovery, biomarker programs for biologics license applications (BLA), supporting product launches and life cycle management.

Before transitioning to industry, where managing CROs and collaborating with internal stakeholders and KOLs have become key responsibilities, critical thinking combined with a self-starter attitude were my keys to become a group leader and founder of 2cSysBioMed (https://2cSysBioMed.com).

I thrive on formulating and answering complex questions on the basis of high-dimensional data. To succeed, I rely on ingenious problem solving, interdisciplinary collaboration and agile project management as well as on my strong practical expertise in laboratory and clinical research, bioinformatics, statistics, software development, science communication and data visualization.

KEY ACHIEVEMENTS

- Contributed to the FDA-approval and launch of Nemolizumab for atopic dermatitis (AD) and prurigo nodularis (PN) via defining the drug's molecular mode of action (MoA).
- Substantially increased R&D efficiency of translational research initiatives and biomarker programs via enabling efficient decision-making on the basis of complex biological data.
- The creation of *Deeply Superficial – Imagining the Human from Molecular Bare Life*. As an art project, it makes tangible the impact of genomics and data science beyond medicine and technology (https://nicolasdelaleu.com/deeply-superficial/).
- Conceptualized and led an "omics" data-focused academic research group that has delivered novel bioinformatics solutions permitting leveraging biological "big data" for developing precision medicine and founding of 2cSysBioMed.
- While working in academia, I secured and managed ≈ $ 1'800'000 in research funds.

WORK EXPERIENCE

2024 –	**Director, Head of Computational Biology & AI (data-driven decision-making at the intersection of science, medical affairs and business strategy)** Galderma SA, Lausanne, Switzerland (on behalf of Oxford Global Resources)
2023 – 2024	**Senior Computational Biologist (delineate nemolizumab's molecular MoA in AD and PN for clinical phase 3 and BLA to FDA)** Galderma SA, Lausanne, Switzerland (on behalf of Oxford Global Resources)
2017 –	**Founder, Chief Data Scientist & Immunologist (data-driven decision-making & data visualization for translational medicine)** 2cSysBioMed, Ticino, Switzerland
2017 – 2020	**Translational Medicine Expert and Bioinformatician (prostate cancer)** Institute of Oncology Research (IOR), Bellinzona, Switzerland
2013 – 2017	**Research Group Leader: Omics Data Analysis and Visualization Group (ODAV)**

University of Bergen (UiB), Norway

2009 – 2013 **Postdoc & Project Manager (bioinformatics & experimental immunotherapy)**
Research Council of Norway (RCN) / PI: Professor R. Jonsson DMD, PhD

2008 **Research Scientist (computational biology & data visualization)**
Innovest, Norway

2002 – 2004 **Scientific Assistant (autoimmunity & Sjogren's syndrome)**
Clinic for Geriatric and Special Care Dentistry, University of Zürich, Switzerland

1999 – 2002 **Bioengineer & Scientific Assistant (inflammation & biocompatibility)**
Laboratory of Oral Cell Biology, University of Bern, Switzerland

1997 – 1999 **Bioengineer (clinical studies, vaccinology & antibodies)**
Crucell (now J & J), Department of Immunology, Bern, Switzerland

RESEARCH STAYS

2017 Computational Biology Unit, ELIXIR, UiB, Norway (6 months) / K. Pertersen PhD

2015 – 2016 Molecular Oncology, IOR, Switzerland (15 months) / Andrea Alimonti MD, PhD

2013 – 2014 Bioinformatics Core Unit & Lymphoma and Genomics Research Program, IOR, Bellinzona, Switzerland (9 months) / Ivo Kwee PhD & Francesco Bertoni MD, PhD

2007 Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, USA / Ammon B. Peck PhD

EDUCATION

2020 – **Art school LeMasterklass with Klavdij Sluban**
Tailor-made master class on contemporary art practice, Paris, France

2005 – 2008 **PhD fellow, Bergen Research School in Inflammation (fellowship from UiB)**
Broegelmann Research Laboratory (BRL), the Gade Institute, UiB, Norway

2004 **FELASA C Researcher in Animal Science**
School of Veterinary Science, University of Oslo, Norway

2004 **Pre-doctoral student (fellowship from the EU's Marie Curie program)**
BRL, the Gade Institute, UiB, Norway

2003 – 2004 **Certificate in Advanced Studies in Science Communication**
IPMZ and IAM, University of Zürich, Switzerland

1994 – 1997 **Bioengineer Federal VET (vaccinology, molecular biology and virology)**
Swiss Institute for Sera and Vaccines (now J & J), Bern, Switzerland

MAJOR GRANTS

2013 **Bergen Medical Research Foundation ≈ $ 750'000.-**
Formation of the Omics Data Analysis and Visualization Group

2009 **The Research Council of Norway ≈ $ 1'300'000.-, UiB tranche ≈ $ 750'000.-**
Mucosal vaccination against autoimmune disease / PI: R. Jonsson DMD, PhD

PUBLICATION METRICS

38 peer-reviewed articles (15 as first or co-first, 8 as corresponding or last author) and 2 book chapters (1 as first author) and 1 PhD thesis (ISBN 978-82-308-0597-8).

Top Journals: Nat Genet, Nat Cancer, Nat Immunol, Kidney Int, Ann Rheum Dis, Nat Commun, Cell Rep, Arthritis Rheum, Arthritis & Rheumatology, Drug Discov Today.

Google Scholar as per 03.01.2026: Citations = 3052, h-index = 28, i10-index = 33

SKILLS / METHODOLOGIES (SELECTION)

Data science & statistics: R, SPSS / 2D & 3D modeling and visualization: R, Cytoscape, Illustrator, Photoshop, Blender / Publishing: InDesign, EndNote, / Web design: Wordpress, CSS, HTML.

Biotechnology: DNA, RNAseq, scRNAseq, genetic engineering, gene regulation & translation / proteomics, FACS, hybridoma technology, western blot, ELISA / quantitative pathology, IHC, confocal 3D & 4D microscopy / *in vitro* & *in vivo* models of vaccinology, autoimmunity & cancer.

ACHIEVEMENTS PER APPOINTMENT

2024 – **Director, Head of Computational Biology & AI (data-driven decision-making at the intersection of science, medical affairs, key opinion leaders and business strategy)**

i) Conceptualize and implement a strategic and methodological framework that allows the efficient use of proprietary, public and real-world data to predict drug response, expand drug indication and assess drug candidates in alignment with science, medical affairs and business strategy. Communicate up to CEO -1.

ii) Reporting to Global Head of Research and Early Development. Deliver KOLs with analyses to further the understanding of nemolizumab's molecular MoA.

2023 – 2024 **Senior Computational Biologist (delineate nemolizumab's molecular MoA in AD and PN for clinical phase 3 and BLA to FDA)**

i) Manage CROs involved and execute the omics data-related analyses plans related to phase 3 clinical studies of nemolizumab in AD and PN.

ii) Write the respective reports and summarize, visualize and communicate the results.

2020 – **Art school LeMasterklass with Klavdij Sluban**

i) Within relational sculptures & musical composition: Completion of three 3D models and one book related to *Deeply Superficial – Imagining the human from molecular bare life* https://nicolasdelaleu.com/deeply-superficial/.

ii) Within contemporary photography: Completion of the artist's book *Noon Moon* https://nicolasdelaleu.com/noon-moon/.

2017 – 2020 **Translational Medicine Expert and Bioinformatician (Prostate Cancer)**

i) Delivered an integrative data analyses platform for drug target identification.

ii) Application of this platform to develop cancer therapy via reshaping the tumor's immune compartment, metabolism and senescence phenotype.

2013 – 2017 **Research Group Leader: Omics Data Analysis and Visualization Group**

i) Increased scope and impact of research projects in the fields of prostate cancer immunotherapy, autoimmune diseases and periodontitis by making 'omics' datasets actionable.

ii) Initiated, funded and supervised further development of 'omics' data analysis and visualization pipelines towards patentable solutions.

iii) Translated systems biomedicine concepts form autoimmunity to cancer immunotherapy.

2009 – 2013 **Postdoc & Project Manager (Bioinformatics & Experimental Immunotherapy)**

iv) Conceptualized novel 'omics' data analysis and visualization pipelines for systems biomedicine and integration of multiomics data.

v) Completed preclinical testing of p277 peptide-based mucosal vaccines as a mean of reinstating immune tolerance in Sjögren's syndrome and type 1 diabetes.

vi) Secured funding to establish the ODAV group at the UiB.

2008 **Research Scientist (Computational Biology & Data Visualization)**

i) Systematic analyses of gene expression datasets form *in vivo* models to deliver data-driven hypotheses for genome-wide association studies.

2005 – 2008 **PhD fellow, Bergen Research School in Inflammation (fellowship UiB)**

i) Completion of the first pre-clinical intervention study at the BRL.

ii) Demonstrated the value of saliva proteomics for prediction of treatment responses.

iii) Based on this work, the BRL received significant funding from the RCN.

2005 **FELASA C Researcher in Animal Science**

Acquired all formal qualifications to conduct and supervise animal experiments.

2004 – 2005 **Pre-doctoral student (fellowship from the EU's Marie Curie program)**

i) Set-up multicolor flow cytometry for single cell immune-cell characterization at the BRL.

ii) Won a competitive PhD fellowship at the UiB.

2002 – 2004 **Scientific Assistant (Autoimmunity & Sjogren's Syndrome)**

i) Developed a Sjögren's syndrome-focused research project tailored to this clinic.

ii) Was awarded a pre-doctoral fellowship in Bergen, Norway.

2000 – 2002 **Bioengineer & Scientific Assistant (Inflammation & Biocompatibility)**

i) Established primary cell lines, *in vitro* transfection models and live cell confocal laser scanning microscopy methodologies to delineate alternative activation pathways and subcellular localization patterns of Interleukin (IL)-1 and IL-18 in local inflammation.

1997 – 1999 **Bioengineer (Clinical Studies, Vaccinology & Antibodies)**

i) Developed SOPs and carried out immunoassays to determine cellular and humoral immune responses induced by vaccines delivered via the oral, nasal and parenteral routes. This data was key to deliver on biomarker criteria required by regualtors.

ii) Produced monoclonal antibodies with hybridoma technology for novel immunoassays.

1994 – 1997 **Bioengineer Federal VET in vaccinology, molecular biology and virology**

i) Participated in the GMP-grade production of lot 15 of the drug Aerugen®.

ii) Expression of LPS O157 from enterohemorrhagic Escherichia coli (EHEC) O157:H7 on Vibrio cholera CVD 103-HgR for developing a live oral EHEC vaccine.

iii) Independent in process control and QA of viral vaccines MMR and influenza.

SUPERVISION AND TEACHING

2011 – 2017 Principal supervisor for PhD fellow Suzanne Ledahl, BVSc
2013 – 2015 Postdoctoral fellow Yogita Sharma PhD and Petra Vogelsang PhD
2005 – 2006 Principal supervisor for A.C. Madureira, MSc, University of Coimbra, Portugal
2005 – 2012 Teaching BRSI (HUIMM901, HUIMM902 & HUIMM903), UiB, Bergen, Norway

CONTINIOUS EDUCATION (SELECTION)

- *Network Biology / Integromics Bioinformatics,* Norbis, Norway (3 days)
- *High-Throughput Genomics,* UiB, Norway (3 days)
- *Advanced Biocomputing,* Professor Scott Santos, Auburn University, USA (4 ECTS)
- *Integrative Bioinformatics,* UiB, Norway (2 ECTS)
- *From Innate to Specific Immunity,* Norway (3 ECTS)
- *Scientific writing practice*, University of Zürich, Switzerland (7 days)
- Multi-color, living cells, 3D & 4D confocal laser scanning microscopy (5 days)
- GMP, GLP and SOP, continuous education at Crucell / Berna Biotech (now J & J)
- *Introspective photography,* Michael Ackerman (6 days)

PERSONAL PROJECTS

- Contemporary art (www.nicolasdelaleu.com).
- Bouldering / climbing on a high-performance level (FB 8B+).

LANGUAGE ABILITIES

English	(fluent)	French	(proficient)
German	(fluent)	Italian	(intermediate)
Norwegian	(proficient)	Russian	(beginner)

REFERENCES (Testimonials @ https://2csysbiomed.com/#testimonials)

Valérie Julia, PhD
Global Head of Research & Early Development
Galderma SA, Lausanne, Switzerland
E-mail: valerie.julia@galderma.com / phone work: +41 76 302 2652

Ekaterina Kotelnikova, PhD
Associate Director for Discovery and Translational Science Consulting
Clarivate PLC, Barcelona, Spain
E-mail: ekaterina.kotelnikova@clarivate.com

Professor Andrea Alimonti, PhD
Director, Switzerland & Professor of Experimental Oncology, ETH Zürich
IOR, Bellinzona, Switzerland
E-mail: andrea.alimonti@ior.iosi.ch / phone work: +41 91 811 1720

Professor Roland Jonsson DMD, PhD
Fmr. Broegelmann Chair of Immunology, UiB, Norway
Department of Clinical Science, University of Bergen
Bergen, Norway
E-mail: roland.jonsson@k2.uib.no

Professor Ammon B. Peck PhD
Fmr. Professor & Assoc. Dean for Research and Graduate Studies, Vet. Med.
University of Florida, Gainesville, USA
E-mail: peck@ufl.edu

Klavdij Sluban
Photographer and Mentor, https://fr.wikipedia.org/wiki/Klavdij_Sluban
92600 Asnières-sur-Seine, France
e-mail: atul@hotmail.fr / Telephone work: + 33 6 0717 2937

PEER-REVIEWED ARTICLES

1) Delaleu N, Marti HP, Strauss P, Sekulic M, Osman T, Tondel C, Skrunes R, Leh S, Svarstad E, Nowak A, Gaspert A, Rusu E, Kwee I, Rinaldi A, Flatberg A, Eikrem O:
Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing.
Kidney Int 2023, 104(4):803-819. IF 2023: 14.8

2) Brina D, Ponzoni A, Troiani M, Cali B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D'Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Ruschoff JH, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J, Alimonti A:
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.
Nat Cancer 2023, 4(8):1102-1121. IF 2023: 23.5

3) Oftedal BE, Delaleu N, Dolan D, Meager A, Husebye ES, Wolff ASB:
Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1.
FEBS Lett 2023, 597(9):1261-1274. IF 2023: 3.0

4) Eikrem O, Lillefosse B, Delaleu N, Strauss P, Osman T, Vikse BE, Debiec H, Ronco P, Sekulic M, Koch E, Furriol J, Leh S, Marti HP:
Network-based assessment of minimal change disease identifies glomerular response to IL-7 and IL-12 pathways activation as innovative treatment target
Biomedicines, 2023, 11, 226. IF 2021: 3.9

5) Emming S, Bianchi N, Montagner S, Polletti S, Balestrieri C, Chirichella M, Delaleu N, Natoli G, Monticelli S:
A molecular network regulating the pro-inflammatory phenotype of human memory T lymphocytes
Nat Immunol 2020, 21(4):388-399. IF 2020: 25.6

6) Di Mitri D, Mirenda M, Vasilevska J, Calcinotto A, Delaleu N, Revandkar A, Gil V, Boysen G, Losa M, Mosole S, Pasquini E, D'Antuono R, Masetti M, Zagato E, Chiorino G, Chiorino, G, Ostano P, Rinaldi A, Gnetti L, Graupera M, Figueiredo Fonseca ARM, Pereira Mestre R, Waugh D, Barry S, De Bono J, Alimonti A:
Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer
Cell reports 2019, 28(8):2156-2168 e2155. IF 2019: 8.1

7) Koch K, Finne K, Eikrem O, Landolt L, Beisland C, Leh S, Delaleu N, Granly M, Vikse BE, Osman T, Scherer A, Marti HP:
Transcriptome-proteome integration of archival human renal cell carcinoma biopsies enables identification of molecular mechanisms.
Am J Physiol Renal Physiol 2019, 316(5):F1053-F1067. IF 2019: 3.2

8) Kaminska M, Aliko A, Hellvard A, Bielecka E, Binder V, Marczyk A, Potempa J, Delaleu N, Kantyka T, Mydel P:
Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas Gingivalis.
J Periodontol 2019 90(6):637-646. IF 2019: 3.7

9) Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Pasquini E, Alajati A, Pinton S Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Masgras I, Rasola R, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni B, Carracedo A, Alimonti A:
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Nat Genet 2018, 50(2):219-228. IF 2018: 25.5

10) Aliko A, Kamińska M, Bergum B, Gawron K, Benedyk M, Lamont RJ, Malicki S, Delaleu N*, Jan Potempa J*, Mydel P*:
Impact of Porphyromonas gingivalis Peptidylarginine Deiminase on Bacterial Biofilm Formation, Epithelial Cell Invasion, and Epithelial Cell Transcriptional Landscape
Scientific reports 2018, **8**(1):14144, *shared last. IF 2018: 4.0

11) Jonsson R, Brokstad KA, Jonsson MV, Delaleu N, Skarstein K:
Current concepts on Sjögren's syndrome – classification criteria and biomarkers

Eur J Oral Sci 2018, 126 Suppl 1:37-48. IF 2018: 1.8

12) Bruserud Ø, Bratland E, Hellesen A, Delaleu N, Reikvam H, Oftedal BE, Wolff AB:
Altered immune activation and IL-23 signaling in response to Candida Albicans in Autoimmune polyendocrine syndrome type 1
Front Immunol 2017, 8:1074. IF 2017: 5.5

13) Binder V, Bergum B, Jaisson S, Gillery P, Scavenius C, Spriet E, Nyhaug A, Roberts HM, Chapple I, Hellvard A, Delaleu N, Mydel P:
The Impact of Fibrinogen Carbamylation on Fibrin Clot Formation and Stability
Thromb Haemost 2017, 117(5):899-910. IF 2017: 5.0

14) Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, Fraering P, Bertoni F, Nepveu A, Alimonti A:
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Nat Commun 2016, 7:13719. IF 2016: 12.1

15) Hellvard A, Zeitlmann L, Heiser U, Kehlen A, Niestroj A, Demuth HU, Koziel J, Delaleu N, Potempa J, Mydel P:
Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.
Scientific reports 2016, 6:31441. IF 2016: 4.3

16) Koro C, Hellvard A, Delaleu N, Binder V, Scavenius C, Bergum B, Głowczyk I, Roberts H, Chapple I, Grant M, Rapala-Kozik M, Klaga K, Enghild J, Potempa J, Mydel P:
Carbamylated LL-37 as a modulator of the immune response.
Innate Immun 2016, 22(3):218-229. IF 2016: 2.3

17) Delaleu N, Mydel P, Brun JG, Jonsson MV, Alimonti A, Jonsson R:
Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome.
Rheumatology (Oxford) 2016, 55(6):1127-1137. IF 2016: 4.8

18) Benedyk M, Mydel PM, Delaleu N, Plaza K, Gawron K, Milewska A, Maresz K, Koziel J, Pyrc K, Potempa J:
Gingipains: Critical Factors in the Development of Aspiration Pneumonia Caused by Porphyromonas gingivalis.
J Innate Immun 2016, 8(2):185-198. IF 2016: 3.9

19) Bergum B*, Koro C*, Delaleu N*, Solheim M, Hellvard A, Binder V, Jonsson R, Valim V, Hammenfors DS, Jonsson MV, Mydel P:
Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity.
Ann Rheum Dis 2016, 75(8):1494-1500, *equal contribution. IF 2016: 12.8

20) Delaleu N, Mydel P, Kwee I, Brun JG, Jonsson MV, Jonsson R:
High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjögren's syndrome.
Arthritis & Rheumatology 2015, 67(4):1084-1095. IF 2015: 9.0

21) Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, L AP, Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A:
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
Nat Commun 2015, 6:7227. IF 2015: 11.3

22) Delaleu N, Nguyen CQ, Tekle, KM, Jonsson R, Peck AB:
Transcriptional landscapes of emerging autoimmunity: transient aberrations in the targeted tissue's extracellular milieu precede immune responses in Sjögren's syndrome
Arthritis Res Ther 2013, 15(5):R174. IF 2013: 4.1

23) Delaleu N, Nguyen CQ, Peck AB, Jonsson R:
Sjögren's Syndrome: Studying the Disease in Mice
Arthritis Res Ther 2011, 13(3):217. IF 2011: 4.4

24) Nordmark G, Kristjansdottir G, Theander E, Appel S, Eriksson P, Vasaitis I, Kvarnström M, Delaleu N, Lundmark P, Lundmark A *et al*:
Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome
Genes Immun 2011 Mar;12:100-9. IF 2011: 3.9

25) Jonsson MV, Reksten TR, Delaleu N, Marthinussen MC:
Diagnostikk av munntørrhet og bruk av saliva som diagnostisk verktøy
Nor Tannlegeforen Tid 2011; 121: 908-13. IF 2011: n/a

26) Delaleu N, Peck AB:
Autoimmunity: limited progress for the patient, despite decades of research
Scand J Immunol 2009, 70:411-4 IF 2009: 2.1

27) Berggreen E, Nyløkken K, Delaleu N, Hajdaragic-Ibricevic H, Jonsson MV:
Impaired vascular responses to parasympathetic nerve stimulation and deficient muscarine receptor activation in submandibular glands of NOD mice
Arthritis Res Ther 2009, 11:R18. IF 2009: 4.5

28) Delaleu N, Jonsson MV, Appel S, Jonsson R:
New concepts in the pathogenesis of Sjögren's syndrome
Rheum Dis Clin N Am 2008, 34:833-45, vii. IF 2008: 2.2

29) Delaleu N, Jonsson R:
Altered fractalkine cleavage results in an organ-specific 17 kDa fractalkine fragment in salivary glands of NOD mice
Arthritis Res Ther 2008, 10:114. IF 2008: 4.5

30) Delaleu N, Madureira AC, Immervoll H, Jonsson R: (Title page illustration)
Inhibition of experimental Sjögren's syndrome through immunization with heat-shock protein 60kDa and its peptide aa437-460
Arthritis Rheum 2008, 58:2318-28. IF 2008: 6.8

31) Delaleu N, Immervoll H, Cornelius J, Jonsson R:
Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations
Arthritis Res Ther 2008, 10:R22. IF 2008: 4.5

32) Jonsson MV, Delaleu N, Jonsson R:
Animal models of Sjögren's syndrome
Clin Rev Allergy Immunol 2007, 32:215-224. IF 2007: 2.1

33) Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K:
Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland
Arthritis Rheum 2006, 54:2300-2305. IF: 7.8

34) Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, Delaleu N, Jonsson R, Centola M:
Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF
Clin Immunol 2005, 117:168-176. IF: 3.2

35) Delaleu N, Jonsson R, Koller MM:
Sjögren's syndrome
Eur J Oral Sci 2005, 113:101-113. IF: 1.8

36) Delaleu N, Jonsson MV, Jonsson R:
Disease mechanisms of Sjögren's syndrome
Drug Discov Today; Disease Mechanisms 2004, 1:329-336. IF: 6.9

37) Delaleu N, Bickel M:
Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation
Periodontol 2000 2004, 35:42-52. IF: 2.5

38) Zehnder M*, Delaleu N*, Du Y, Bickel M:
Cytokine gene expression--part of host defense in pulpitis
Cytokine 2003, 22:84-88, *equal contribution. IF: 2.2

BOOK CHAPTERS

1) Delaleu N, Manoussakis MN, Moutsopoulos HM, Jonsson R:
Etiology and Pathogenesis of Sjögren's Syndrome with Special Emphasis on the Salivary Glands
Sjögren's syndrome: Current topics of pathogenesis and therapy; edited by Fox RI

2) Jonsson MV, Delaleu N, Marthinussen MC, Jonsson R:
Oral and Dental Manifestations of Sjögren's Syndrome: Current Approaches to Diagnostics and Therapy
Sjögren's syndrome: Current topics of pathogenesis and therapy; edited by Fox RI

DISSERTATION FOR THE DEGREE PHILOSOPHIAE DOCTOR; DEFENDED 20.06.2008

Delaleu N: (ISBN 978-82-308-0597-8)
The Autonomy of Different Aspects of Sjögren's Syndrome and their Treatment in an Experimental Model: The use of comprehensive biomarker analyses to characterize the disease and the effect of heat-shock proteins in treatment intervention

POPULAR SCIENTIFIC ARTICLES

1) Delaleu N:
Die Wahrheit über Nemo (the truth about Nemo)
Advanced Studies in Science Communication, 2004
2) Alsnes R in collaboration with Delaleu N:
Du finn det i spyttet (one finds it in saliva)
Revmatikeren 2008, 5:20-21.